XED 60

Drug Profile

XED 60

Alternative Names: XED-60

Latest Information Update: 09 Jun 2016

Price : $50

At a glance

  • Originator Lion Corporation
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 30 Nov 2015 Lion Corporation completes a phase II trial in Dry eye in Japan before March 2016 (Ophthalmic) (JapicCTI-152829)
  • 11 Mar 2015 Phase-II clinical trials in Dry eyes in Japan (Ophthalmic) (JapicCTI-152829)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top